Article Text

PDF
Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn’s disease
  1. Nobuhide Oshitani1,
  2. Hirokazu Yamagami2,
  3. Kenji Watanabe2,
  4. Kazuhide Higuchi2,
  5. Tetsuo Arakawa2
  1. 1Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan
  2. 2Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka Japan
  1. Correspondence to:
    Dr Nobuhide Oshitani
    Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1–4–3, Asahi-machi, Abeno-ku, Osaka 545–8585, Japan; nobu{at}med.osaka-cu.ac.jp

Statistics from Altmetric.com

Fibrosis and strictures are common and irreversible complications of Crohn’s disease that potentially necessitate bowel resection. Tranilast, N-(3’,4’-dimethoxycinnamoyl) anthranilic acid, inhibits keloid scar formation through the inhibition of production of metalloproteinases and tissue inhibitor of metalloproteinase-1 from neutrophils.1 Please check the phrase “inhibition of … neutrophils” is OK Tranilast has been shown to inhibit fibrosis in various experimental models.2–4 Randomised, double-blind, placebo-controlled studies have shown substantial inhibition by tranilast of restenosis of coronary arteries.5–7 A case report has demonstrated the efficacy of long-term administration of tranilast in inflammatory endobronchial stenosis.8

Between June 2001 and July 2005, 24 patients with quiescent Crohn’s disease with non-symptomatic intestinal strictures were recruited. Baseline intestinal stricture was evaluated by small bowel barium enteroclysis, or …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.